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Introduction
Drug delivery to the brain for the treatment of a wide variety of diseases is hampered by the blood-brain barrier (BBB). In recent years, intranasal (i.n.) administration has come to light as an effective and noninvasive means to circumvent the BBB for a variety of substances, including polypeptides, liposomes, virus vectors for gene therapy, and stem cells (Lochhead and Thorne, 2012a) (Dhuria et al., 2010) . These substances not only reach the brain tissue, but for bioactive compounds such as insulin (Craft et al., 2012) (Benedict et al., 2011 ) (Reger et al., 2008 , oxytocin (Veening and Olivier, 2013) , and leptin (Schulz et al., 2012) , do so in levels sufficient to cause significant behavioral changes in both patients and animal models of disease.
Albumin, the preeminent transport protein in the blood, is emerging as a versatile transport molecule for targeted drug delivery (Kratz, 2008) , and albumin has recently gained attention in the field of pharmaceutical development for its ability to prolong the half-life and stability of bioactive compounds (Elsadek and Kratz, 2012) . While albumin binding proteins such as gp60 (albondin) facilitate transcytosis of albumin in peripheral capillaries, there is low expression in brain endothelial cells (Schnitzer, 1992) , and albumin has been shown to not cross JPET #216705
Methods
Animals: Male CD1 mice, 8 weeks of age, purchased from Charles River Laboratories (Wilmington, MA) were used throughout these experiments. Mice had free access to food and water and were on a 12 hour light-dark cycle. All studies were performed under approved IACUC protocols at and by an AAALAC accredited facility.
Iodination of Albumin and Leptin: Bovine serum albumin (BSA) (Sigma-Aldrich; St. Louis, MO) and murine leptin (R&D Systems Inc.; Minneapolis, MN) were radioactively labeled with 125 I by the chloramine-T method (Greenwood and Hunter, 1963) . Briefly, 10 Ringers solution with or without 1% BSA. An acid precipitation using 15% trichloroacetic acid was then performed to assess purity. The percent of radioactivity precipitated was calculated by the following formula:
JPET #216705 administered intranasally (i.n.) via a micropipette tip inserted 4 mm into the left nostril of each mouse. I-Lep was injected in PB with or without 1% BSA (1g/100 ml) added to the PBS vehicle.
Tissue Collections: Male CD1 mice were anesthetized and administered i.n. I-Alb or I-Lep as above. Blood was collected from the carotid artery and the whole brain was removed at a predetermined time point after i.n. administration. Time points were 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 6 hours. The brain was dissected using the method of Glowinski and Iversen (Glowinski and Iversen, 1966) on ice into 11 regions of olfactory bulb, occipital cortex, striatum, frontal cortex, hypothalamus, thalamus, hippocampus, parietal cortex, cerebellum, midbrain, and pons-medulla, and each region was weighed. The collected whole blood was allowed to clot at room temperature, centrifuged at 5400 g for 10 min at 4°C and 50 μ l of resulting serum was removed for use. The level of radioactivity in each of the 11 regions and the serum sample was determined in a Wizard2 Automatic Gamma Counter (Perkin Elmer;
Waltham, MA) by counting for 30 min. Values for whole brain were calculated by summing the regional weights and regional levels of radioactivity of all tissue samples except the olfactory bulb. The percent of the injected dose present in a ml of serum (%Inj/ml) was calculated with the following formula:
where Inj is the CPM administered and CPM/ml is the level of radioactivity in a ml of serum.
The percent of the injected dose taken up per gram of brain region (%Inj/g) was calculated at each time with the following formula:
This article has not been copyedited and formatted. The final version may differ from this version. where W is the weight of the given brain region in grams and CPM/R is the level of radioactivity in the brain region. The rate at which i.n. I-Alb would have to enter into blood to reach the levels measured in blood was calculated by the formula:
where T is the entry rate into blood in %Inj/min, P is the level of I-Alb measured in serum in %Inj/ml at time t, Vd is volume of distribution in ml, t is sampling time in min, and K = (0.693/t 1/2 ), where t 1/2 is the half-time clearance of I-Alb from blood after intravenous injection.
The values used for t 1/2 and Vd for I-Alb were 316 min and 1.76 ml as previously measured (Banks and Broadwell, 1994) .
Acid Precipitations: Male CD1 mice were anesthetized and administered i.n. I-Alb as above.
Blood was collected from the external jugular vein and the whole brain was removed at 10 minutes or 60 minutes after the i.n. administration of I-Alb (n=7 mice/group). Olfactory bulb, cortex, and cerebellum were dissected from the remainder of the brain on ice and collected in 1ml 1% BSA in LR. Tissue samples were homogenized in a Mini-BeadBeater™ (BioSpec Products, Inc.; Bartlesville, OK) twice (30 sec each pulse; 4800 rpm), then centrifuged at 10000 g for 20 min at 4°C. Whole blood samples were allowed to clot at room temperature and then centrifuged at 5400 g for 10 min, also at 4°C. A 50 µl portion of the supernatant from each sample was used to perform an acid precipitation using 15% trichloroacetic acid. To determine the amount of degradation that occurred with processing, 400,000 CPM was added in vitro to a JPET #216705
sample of serum or a brain region obtained from a mouse that had not received i.n. I-Alb (n=2).
Samples were then processed as above. After addition of TCA, the serum, brain, and processing controls were centrifuged at 5000 g for 10 min at 4°C, and the supernatant was separated from the pellet. The radioactivity of both pellet and supernatant was determined in a Wizard2
Automatic Gamma Counter (Perkin Elmer; Watham, MA) by counting for 30 min, and percent of radioactivity precipitated (AP %) was calculated by the following formula:
The percent precipitated from samples was divided by that which precipitated in the processing controls and multiplied by 100 to give an index of intact I-Alb.
I-Alb vs I-Alb + unlabeled Albumin: Male CD1 mice were anesthetized as described above and administered i.n. I-Alb with or without 10 μ g (2μg/μl in PB) of unlabeled albumin (n = 29/group).
Blood was collected from the external jugular vein and the whole brain was removed 30min after the i.n. administration. Olfactory bulb, cortex, and cerebellum were dissected from the remainder of the brain on ice, each region was weighed, and the level of radioactivity was determined in a Wizard2 Automatic Gamma Counter (Perkin Elmer; Waltham, MA) by counting for 30min.
Whole brain mass and radioactivity were determined by combining the mass and radioactivity of all regions except olfactory bulb. Whole blood was allowed to clot at room temperature, was centrifuged at 5400 g for 15min at 4°C, and the radioactivity of 50 Whole brain mass and radioactivity were determined by combining the mass and radioactivity of all regions except OB. Whole blood was allowed to clot at room temperature, was centrifuged at 5400g for 15min at 4°C, and the radioactivity was counted in 50μl of the resulting serum for 
Results
Our first goals were to determine whether i.n. administered albumin reaches the brain, where in the brain it distributes, and the time course of delivery and clearance. We therefore harvested the brain over a 6 h period, dividing it into the 10 regions of Glowinski and Iversen (Glowinski and Iversen, 1966) plus the olfactory bulb. Figure 1 shows the percent of i.n.
administered I-Alb taken up by each brain region (%Inj/g) at the various time points and shows varying regional patterns of I-Alb uptake and clearance.
All brain regions showed uptake of I-Alb at 5 minutes, the first time point examined ( Figure 1 ). The highest peaks are seen for olfactory bulb (1.06%inj/g ± 0.35, n=15) and striatum (0.45%inj/g ± 0.21, n=10). In the frontal cortex, parietal cortex, occipital, thalamus, cerebellum, and pons-medulla, the concentration of I-Alb was highest at 5min, after which it decreased gradually. Among the three cortical regions, frontal cortex and occipital cortex remained steady at 0.10-0.15 %inj/g through the first 2 hours, whereas the parietal cortex decreased earlier, having undetectable levels by 2 hours. Several regions demonstrated distinct peaks in %inj/g, including the olfactory bulb at 10 min, the striatum at 30 min, and the midbrain and hypothalamus at 60 min. The cerebellum had the lowest peak level and was the first to be cleared with undetectable levels 60 min after i.n. administration of I-Alb. I-Alb is essentially cleared from all regions by 4 hours.
The %inj/ml of serum ( Figure 2 ) remained fairly steady at 1%inj/ml, trending upwards at the 6 hour time point. The rate at which I-Alb would enter the blood stream to produce these levels ranged from about 0.32 %Inj/min at 5 min to a low of 0.012 %Inj/min at 360 min.
Multiplying time by %Inj/min showed that about 1.5-4% of the i.n. dose of I-Alb entered the blood stream during the course of the study.
To determine the extent to which the radioactivity observed in the brain after i.n.
administration of I-Alb accurately represents the presence of the administered protein, we performed an acid precipitation of the tissue. Because a majority of the regions showed the strongest signal within the first hour, we chose to examine time points 10 and 60 minutes after i.n. administration. Four regions were examined, and the radioactivity of each sample after precipitation is reported as a percent of a matched processing control (Table I) . When measurements were pooled from all regions and both time points, the mean adjusted percent was 61.36% (± 9.40%), representing the portion of radioactivity measured throughout these experiments that reliably signifies intact I-Alb. No statistical differences were seen in any regions between the two time points (p>0.05 by 2-way ANOVA).
To investigate the dose dependence of albumin uptake, we administered 400,000 CPM of I-Alb with and without additional unlabeled albumin, the results of which are shown in unlabeled albumin versus 4.645 ± 1.007 without, p<0.05). Changes in olfactory bulb and cerebellum were not significant.
Cellular mechanisms for I-Alb uptake into brain and blood were studied by administering agents 30 min before I-Alb i.n. administration and harvesting brains 15 min after the i.n.
administration. The agents were phenylarsine oxide, filipin, LY294002, and phorbol 12-myristate 13-acetate (PMA), lidocaine, histamine, monensin, and verapamil. DMSO or MeOH were used as controls, depending on the solubility of the inhibitor. Only PMA had a statistically significant effect (Figure 4) , increasing uptake at the olfactory bulb and cortex, but with no effect on cerebellum, or whole brain. PMA had no effect on serum levels and the other agents were without effects on brain or serum levels (data not shown).
The ability of albumin to influence brain distribution of substances administered by the i.n. route was tested by examining the distribution of I-Lep given with or without albumin included in the i.n. injection. Figure 5 shows that co-administration with albumin decreased ILep entry into blood and uptake by the cerebellum, but increased hypothalamic uptake. There were also statistical trends for decreasing uptakes by the olfactory bulb and whole brain, but without an influence on hippocampus.
Discussion
Intranasal administration is a promising approach for delivery of biologicals to the brain (Frey, 2002; Lochhead and Thorne, 2012b) . However, it is unknown which substances can or cannot use this route, nor is it known what cellular mechanisms underlie this uptake. Here, we investigated albumin uptake after intranasal administration. If albumin were to be taken up after intranasal administration, it might act as a binder and carrier, helping to direct substances to showed highest levels of uptake at the first time point, after which I-Alb was gradually cleared.
The rate of clearance showed regional differences, but I-Alb was effectively cleared from all regions by the 4 hour time point. The striatum and midbrain exhibited distinct peaks in concentration, consistent with active uptake or transient sequestration of I-Alb in these regions.
These patterns differ from those seen after i.n. administration of other peptides, including pituitary adenylate cyclase activating polypeptide (PACAP) (Nonaka et al., 2012) , the angiotensin antagonist GR138950 (Charlton et al., 2008) , and testosterone (Banks et al., 2009 ).
This article has not been copyedited and formatted. The final version may differ from this version. We found very little I-Alb entering the blood stream when assessed either as the percent of the injected dose that accumulated in blood or when calculated as a transport rate. The transport rate suggests that most entry into blood occurs early and that less than 4% of the injected dose reaches the blood stream. This is even less than other biologicals given by the i.n.
route (Banks et al., 2004) and suggests that co-administration with albumin may act to keep the co-administered substance within the CNS.
In these experiments, we sought to characterize the mechanism of albumin uptake. The decreases in I-Alb uptake by whole brain and cortex seen when co-administered with unlabeled albumin may indicate competition for a saturable mechanism. The decrease in the I-Alb level in serum seen with co-administration of unlabeled albumin supports the idea of dose-dependent uptake. However, levels in the olfactory bulb were not decreased, suggesting that the dose dependence may have more to do with distribution within the CNS after initial entry than with entry itself.
We saw that pretreatment with PMA increased uptake of I-Alb in the olfactory bulb and cortex, but not cerebellum or whole brain. This suggests a role for PKC signaling in the active nose-to-brain transport of I-Alb (Wu-Zhang and Newton, 2013). More specifically, PMA can stimulate fluid phase transcytosis, the same pathway that albumin uses to cross endothelial cells (Guillot and Audus, 1990) . Phenylarsine oxide, which has effects on N-type Ca2 + channel currents (Searl and Silinsky, 2000) , protein tyrosine phosphatases (Lohmann et al., 2004) , and phosphatidylinositol 4-kinase (Wiedemann et al., 1998) 1983) was without effect on i.n. I-Alb uptake. The same was true of verapamil, the L-and Ttype Ca + channel blocker (Bergson et al., 2011) , which can also inhibit P-glycoprotein, an ATPdependent drug transport protein (Schinkel, 1999) . Albumin-binding proteins, such as endothelial membrane-associated gp60 (albondin) (Schnitzer, 1992) , use caveolae-dependent mechanisms to transport albumin from peripheral blood vessel lumen to interstitium, and are inhibited by filipin (Schnitzer et al., 1994; Tiruppathi et al., 1997) , a cholesterol-binding agent that inhibits caveolae-dependent transcytosis (Schnitzer et al., 1994) . Pretreatment with filipin did not affect I-Alb uptake here, indicating that i.n. transport of albumin is not dependent on caveolae. The phosphoinositide-3-kinase inhibitor LY294002 was also without effect. Monensin, a compound that inhibits acidification of intracellular organelles to prevent endocytosis and delivery of macromolecules to lysosomes, had no effect on albumin transport (Hastings et al., 1994) . Lidocaine, which acts on axons of sensory neurons to block conduction of action potentials by closing voltage-dependent Na + channels, has an attenuating effect on transport of materials in axons, but no effect on albumin (Lavoie et al., 1989; Hiruma et al., 2008) . Also, vasogenic agents such as histamine, did not increase transport of albumin, despite increasing BBB permeability (Stamatovic et al., 2008) .
The consideration that albumin can be used to aid in the uptake or targeting of other biologicals was confirmed in our study with I-Lep. Leptin is a protein of 16 kDa that has effects on both feeding and cognition (Pelleymounter et al., 1995; Farr et al., 2006) . As such, it has been considered for development both as an anorectic and as a treatment for cognitive impairments.
However, the anorectic effects, although desirable in the treatment of obesity, would be a serious untoward effect in the treatment of dementia. Here, albumin had several beneficial effects on i.n. clearance from brain, it increased its uptake to hypothalamus which would supposedly enhance its potency as an anorectic, and it decreased its uptake to non-target sites such as cerebellum and possibly olfactory bulb and whole brain.
In conclusion, we found that I-Alb was taken up by and distributed throughout brain after i.n. administration, with little I-Alb entering blood. I-Alb uptake was dose-dependent and stimulated by PMA. Albumin influenced the distribution of I-Lep, suggesting that i.n. albumin may be used to deliver substances to the CNS. Our observation that albumin readily reaches the Values were steady at about 1%inj/ml, with the peak value at 6 hours. Rates of entry into serum during same time course (right Y axis). 
